title: Prevention of Bone Metastases in Breast Cancer Patients. Therapeutic Perspectives.
abstract: One in four breast cancer patients is at risk of developing bone metastases in her life time. The early prevention of bone metastases is a crucial challenge. It has been suggested that the use of zoledronic acid (ZOL) in the adjuvant setting may reduce the persistence of disseminated tumor cells and thereby might improve outcome, specifically in a population of patients with a low estrogen microenvironment. More recently, the results of a large meta-analysis from 41 randomized trials comparing a bisphosphonate (BP) to placebo or to an open control have been presented at the 2013 San Antonio Breast Cancer Meeting. Data on 17,016 patients confirm that adjuvant BPs, irrespective of the type of treatment or the treatment schedule and formulation (oral or intra-venously (IV)), significantly reduced bone recurrences and improved breast cancer survival in postmenopausal women. No advantage was seen in premenopausal women. BPs are soon likely to become integrated into standard practice. Published data on the mechanisms involved in tumor cell seeding from the primary site, in homing to bone tissues and in the reactivation of dormant tumor cells will be reviewed; these might offer new ideas for innovative combination strategies.
authors.affiliation: Department of Medical Oncology, Institut Curie, 26 Rue d'Ulm, Paris 75005, France. philippe.beuzeboc@curie.net.
authors.forename: Philippe
authors.initials: P
authors.lastname: Beuzeboc
authors.affiliation: Department of Medical Oncology, Institut Curie, 26 Rue d'Ulm, Paris 75005, France. suzy.scholl@curie.fr.
authors.forename: Suzy
authors.initials: S
authors.lastname: Scholl
keywords: adjuvant treatment; bisphosphonates; bone metastasis; breast cancer; denosumab; neoadjuvant treatment; osteonecrosis of the jaw; zoledronic acid